A comparative approach to topical cyclosporine therapy

Eye
D L Williams

Abstract

Topical cyclosporine has been used by veterinary ophthalmologists since 1989 for the treatment of ocular surface inflammatory disease and keratoconjunctivitis sicca (KCS). As well as ameliorating clinical signs of ocular surface lymphocyte-driven inflammation in the dog, cat and horse, topical cyclosporine significantly raises tear production in both normal and KCS-affected animals. A licensed ointment preparation of 0.2% cyclosporine, Optimmune (Schering-Plough), is now available for administration to dogs. In this paper we examine the mechanisms by which cyclosporine exerts both its immunomodulatory and its lacrimogenic actions. The pharmacokinetics of topical cyclosporine are examined to determine whether these effects are truly local or are influenced by generalised immunosuppression caused by systemic absorption of topically applied drug. The paper reviews the few side effects of cyclosporine preparations in the experience of veterinary ophthalmologists and the experimental evidence which appears to implicate the vehicle rather than the active agent cyclosporine as causing many of these effects. Given that topical cyclosporine has been so widely accepted as a valuable ophthalmic preparation in the veterinary world and lice...Continue Reading

References

Jul 1, 1976·Agents and Actions·J F BorelH Stähelin
Jan 1, 1992·Annual Review of Immunology·N H Sigal, F J Dumont
Nov 1, 1991·Ophthalmology·J H Bleik, K F Tabbara
Mar 1, 1991·The Journal of Experimental Medicine·N H SigalS L Koprak
Jul 1, 1990·The Journal of Allergy and Clinical Immunology·A M IraniL B Schwartz
May 15, 1990·American Journal of Ophthalmology·J T LiegnerJ H Wild
Feb 15, 1989·American Journal of Ophthalmology·E J HollandR B Nussenblatt
Aug 1, 1989·The British Journal of Ophthalmology·M Diaz-Llopis, J L Menezo
Jan 1, 1987·The British Journal of Ophthalmology·J C Hill, P Potter
Mar 17, 1988·The New England Journal of Medicine·P F BougneresJ L Chaussain
Oct 1, 1987·The Journal of Experimental Medicine·D A Jabs, R A Prendergast
Nov 1, 1986·The British Journal of Ophthalmology·T A Bell, A G Hunnisett
Oct 1, 1985·Archives of Ophthalmology·R B NussenblattA G Palestine
Jan 1, 1985·Archives of Ophthalmology·M W MostellerH E Kaufman
Jan 31, 1985·Documenta Ophthalmologica. Advances in Ophthalmology·P J KruitJ S Stilma
Jan 1, 1985·Cornea·F Hoffmann, M Wiederholt
Jul 1, 1969·Archives of Ophthalmology·O P van Bijsterveld
Dec 1, 1984·Archives of Ophthalmology·H M BoisjolyN H Park
Jul 30, 1983·Lancet·R B NussenblattI Gery
Jun 29, 1984·Biochemical and Biophysical Research Communications·D H RussellB E Magun
Dec 1, 1983·Antimicrobial Agents and Chemotherapy·T N Kirkland, J Fierer
Mar 1, 1980·The British Journal of Ophthalmology·W F ShepherdB R Jones
May 1, 1982·The British Journal of Ophthalmology·T A BellK G McCullagh
Apr 1, 1981·The Journal of Clinical Investigation·R B NussenblattI Gery
Mar 1, 1994·Cornea·J M Benítez del CastilloJ García Sánchez
Aug 12, 1995·The Veterinary Record·R A ReadJ Sansom

❮ Previous
Next ❯

Citations

Sep 30, 2000·Advances in Therapy·J D NelsonJ D Hirsch
Jul 25, 2013·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Christoph LuschmannAchim Goepferich
Nov 7, 2003·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·F LallemandR Gurny
Apr 13, 2004·Cornea·Altug CetinkayaAysel Pelit
Sep 20, 2005·The British Journal of Ophthalmology·S Tatlipinar, E K Akpek
Jan 10, 2001·Journal of the American Veterinary Medical Association·S O CanappD P O'Brien
May 24, 2012·TheScientificWorldJournal·Burçin YavuzNurşen Unlü
Nov 9, 2005·Journal of Glaucoma·Frank A LattanzioRobert C Allen
Jan 4, 2008·Expert Opinion on Drug Safety·Shahram Kashani, Ali A Mearza
Oct 27, 2009·Journal français d'ophtalmologie·F Brignole-BaudouinC Baudouin
Feb 27, 2008·The Veterinary Clinics of North America. Small Animal Practice·David L Williams
Aug 24, 2005·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Nadav BelfairTova Lifshitz
Apr 16, 2016·Drug Discovery Today·Priyanka Agarwal, Ilva D Rupenthal
May 8, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·Marta Rodriguez-AllerRobert Gurny
May 1, 1997·Cephalalgia : an International Journal of Headache·L SchmettererE A Singer
Jul 14, 2001·Journal of the European Academy of Dermatology and Venereology : JEADV·G A Vena, N Cassano
Jul 9, 2014·Ophthalmology and Eye Diseases·Clyde Schultz
May 31, 2018·Expert Opinion on Pharmacotherapy·Konstadinos G Boboridis, Anastasios G P Konstas
Feb 5, 2005·Transplant International : Official Journal of the European Society for Organ Transplantation·Thomas ReinhardRainer Sundmacher
Feb 7, 2019·Veterinary Ophthalmology·Juliana Kravetz de OliveiraFabiano Montiani-Ferreira
Mar 12, 2017·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·P MaierT Reinhard
Aug 26, 2010·Ocular Immunology and Inflammation·Canan Asli UtineEsen K Akpek
Dec 12, 2019·Eye·David L Williams
Dec 8, 2020·Expert Opinion on Drug Delivery·Michele FigusChiara Posarelli
Apr 3, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Leslie RebiboSimon Benita

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.